HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsang, K.-L. Articles by Lo, S.-K. Search for Related Content PubMed PubMed Citation Articles by Tsang, K.-L. Articles by Lo, S.-K.

Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations

From the Division of Neurology (Drs. Tsang and Ho), University Department of Medicine, University of Hong Kong; and the Department of Rehabilitation Sciences (Professor Lo), Hong Kong Polytechnic University, Hong Kong, China.

Address correspondence and reprint requests to Dr. Ho, Division of Neurology, University Department of Medicine, Queen Mary Hospital, Hong Kong, China.

OBJECTIVE: To test the efficacy, tolerance, and safety of low-dose oral estrogen in postmenopausal women with PD associated with motor fluctuations.

BACKGROUND: Motor fluctuations in PD may be predictable or unpredictable, and eventually affect most patients after long-term levodopa therapy. Although estrogen can modulate nigrostriatal dopamine levels, its effects on PD are unclear.

METHODS: Patients were randomized to receive conjugated estrogen (oral Premarin 0.625 mg daily; n = 20) or placebo (n = 20) in a double-blind, parallel-group, prospective study over 8 weeks. Existing antiparkinsonian drug regimes were kept unchanged. Changes in "on" and "off" periods using patient diaries, Unified Parkinson’s Disease Rating Scale (UPDRS) score, timed tapping score, and Hamilton Depression Scale score were determined by one rater. Subgroup analyses were also performed on patients with only predictable motor fluctuations.

RESULTS: Both treatment groups were similar in age, duration of disease and menopause, antiparkinsonian medication, and compliance with test medication and diary assessments. "On" and "off" times, and motor score (UPDRS subscale III) improved with estrogen, using the Mann–Whitney U test (p < 0.05 after Bonferroni adjustment). Mean "on" time improved by 7% (9 hours/week of awake time) in estrogen-treated patients versus a deterioration of 0.5% (1.4 hours) in placebo-treated patients (95% confidence interval, [CI] of mean difference, 5.73 to 14.9). Mean "off" time improved by 4% (4.4 hours/week of awake time) in estrogen-treated patients versus no change in placebo-treated patients (95% CI, 1.54 to 7.16). Mean subscale III score improved by 3.5 points in estrogen-treated patients versus 0.4 in placebo-treated patients (95% CI, 1.02 to 5.18). No other significant changes were observed (p > 0.05). Subgroup analyses in patients with only predictable motor fluctuations showed similar results, except improvement in mean subscale III score was marginally not significant (p = 0.07; 95% CI, 1.06 to 6.24). Five patients on estrogen had facial flushing, three had lower abdominal discomfort, and two had mild withdrawal vaginal bleeding. The adverse events were mild and resolved without sequelae.

CONCLUSION: Low-dose estrogen is a safe and effective adjunct therapy to existing antiparkinsonian treatment in reducing motor disability in postmenopausal women with PD associated with motor fluctuations.

Key words: PD—Postmenopausal—Estrogen—Motor fluctuations.

This article has been cited by other articles:

				M. D. Price and L. M Shulman Management of Parkinson's disease in older women Menopause Int, March 1, 2008; 14(1): 38 - 39. [Abstract] [Full Text] [PDF]

				S. A. Gardiner, M. F. Morrison, P. D. Mozley, L. H. Mozley, C. Brensinger, W. Bilker, A. Newberg, and M. Battistini Pilot Study on the Effect of Estrogen Replacement Therapy on Brain Dopamine Transporter Availability in Healthy, Postmenopausal Women Am J Geriatr Psychiatry, December 1, 2004; 12(6): 621 - 630. [Abstract] [Full Text] [PDF]

				A. Ascherio, M. G. Weisskopf, E. J. O'Reilly, M. L. McCullough, E. E. Calle, C. Rodriguez, and M. J. Thun Coffee Consumption, Gender, and Parkinson's Disease Mortality in the Cancer Prevention Study II Cohort: The Modifying Effects of Estrogen Am. J. Epidemiol., November 15, 2004; 160(10): 977 - 984. [Abstract] [Full Text] [PDF]

				P. Ragonese, M. D'Amelio, G. Salemi, P. Aridon, M. Gammino, A. Epifanio, L. Morgante, and G. Savettieri Risk of Parkinson disease in women: Effect of reproductive characteristics Neurology, June 8, 2004; 62(11): 2010 - 2014. [Abstract] [Full Text] [PDF]

				L. J. Currie, M. B. Harrison, J. M. Trugman, J. P. Bennett, and G. F. Wooten Postmenopausal Estrogen Use Affects Risk for Parkinson Disease Arch Neurol, June 1, 2004; 61(6): 886 - 888. [Abstract] [Full Text] [PDF]

				A. Ascherio, H. Chen, M.A. Schwarzschild, S.M. Zhang, G.A. Colditz, and F.E. Speizer Caffeine, postmenopausal estrogen, and risk of Parkinson's disease Neurology, March 11, 2003; 60(5): 790 - 795. [Abstract] [Full Text] [PDF]

				R. G. Holloway and A. W. Dick Clinical trial end points: On the road to nowhere? Neurology, March 12, 2002; 58(5): 679 - 686. [Abstract] [Full Text] [PDF]